UroGen Pharma Prices Public Offering of Shares and Warrants

PRINCETON, N.J.-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on the development and commercialization of innovative treatments for urothelial and specialty cancers, has announced the pricing for a public offering. The offering includes 5,000,000 ordinary shares priced at $17.50 each. Additionally, the company is issuing pre-funded warrants to certain investors, allowing the purchase of 1,142,857 ordinary shares at a price of $17.499 per warrant, which is nearly equivalent to the public offering price minus the $0.001 exercise price for each pre-funded warrant.

The gross revenue from this offering is anticipated to be around $107.5 million before the deduction of underwriting discounts, commissions, and estimated expenses. UroGen has also provided the underwriters a 30-day option to purchase up to an additional 921,428 ordinary shares at the public offering price, excluding underwriting discounts and commissions. The closure of this offering is anticipated to occur on June 20, 2024, subject to customary closing conditions.

TD Cowen and Guggenheim Securities are the joint book-running managers for this offering. Oppenheimer & Co. is acting as the lead manager, while Ladenburg Thalmann is the co-manager. H.C. Wainwright & Co. is serving as the financial advisor for the offering.

The offering is being conducted under a shelf registration statement on Form S-3, which includes a base prospectus filed with the Securities and Exchange Commission (SEC) and declared effective on November 29, 2022. Preliminary prospectus supplements and accompanying prospectuses have been filed with the SEC and are accessible on the SEC’s official website. Final versions of these documents will also be filed with the SEC and made available through the same platform. Interested parties may obtain copies of the final prospectus supplement and accompanying prospectuses by contacting TD Securities (USA) LLC at their New York address, by telephone, or via email. Similarly, Guggenheim Securities, LLC can provide these documents upon request through their Equity Syndicate Department.

This announcement does not constitute a solicitation to buy or an offer to sell these securities, nor will any sale occur in any jurisdiction where such an offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that jurisdiction.

About UroGen Pharma Ltd.
UroGen Pharma Ltd. is committed to creating and advancing innovative treatments for urothelial and specialty cancers, aiming to provide better options for patients. The company has developed RTGel® reverse-thermal hydrogel, a unique sustained-release, hydrogel-based platform technology. This technology potentially enhances the therapeutic profiles of existing drugs by allowing prolonged exposure of the urinary tract tissue to medications, making local therapy more effective. UroGen’s first product is designed to treat low-grade upper tract urothelial cancer, and their investigational treatment, UGN-102 (mitomycin) for intravesical solution, aims to treat patients with low-grade non-muscle invasive bladder cancer non-surgically. The company is headquartered in Princeton, NJ, and operates in Israel.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!